查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046612

尼古丁替代療法市場：全球產業規模、市場佔有率、趨勢、機會和預測（按產品、分銷管道和地區分類）、競爭格局（2021-2031 年）

Nicotine Replacement Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球尼古丁替代療法 (NRT) 市場預計將從 2025 年的 550.9 億美元大幅成長至 2031 年的 888.4 億美元，複合年成長率達到 8.29%。

尼古丁替代療法（NRT）包括經醫學核准的產品，例如貼片、口香糖、含片和吸入器。這些產品旨在提供適量的尼古丁，緩解戒斷症狀，且不含可燃香菸中的有害毒素。該市場的成長主要得益於全球範圍內對菸草使用的更嚴格監管，以及公眾對吸菸相關嚴重健康風險的認知不斷提高，這從根本上支撐了對戒煙輔助劑的需求。世界衛生組織（WHO）的報告也印證了這一趨勢：到2025年，全球菸草使用者人數將減少至約12億，這顯示這些公共衛生措施正在對戒菸行為產生顯著影響。

市場概覽
預測期 2027-2031
市場規模（2025 年） 550.9億美元
市場規模（2031年） 888.4億美元
複合年成長率（2026-2031） 8.29%
快速成長的細分市場 電子菸
最大的市場 北美洲

市場促進因素

全球尼古丁替代療法 (NRT) 市場的主要驅動力是消費者對可燃菸草相關嚴重健康風險的認知不斷提高，促使吸菸者尋求經臨床驗證的戒煙輔助劑。公共衛生宣傳活動有效地強調了吸煙與危及生命的疾病之間的聯繫，從而促使人們改變行為，並更多地採用口香糖、貼片和含片等 NRT 產品作為危害緩解策略。美國癌症協會報告稱，2023 年美國成年人吸菸率創歷史新低，僅 11%，這反映了人們對健康風險認知提高所帶來的顯著影響。同時，技術進步透過創新的給藥系統提高了 NRT 的有效性和使用者依從性，這些系統能夠更真實地模擬吸煙的生理滿足感，且無毒性，從而有效降低了複吸率。例如，Achieve Life Sciences 公司基於胞胞嘧啶的新型治療方法在 2025 年 4 月進行的 ORCA-3 臨床試驗中，12 週連續戒斷率達到 30.3%，具有統計學意義，顯著優於安慰劑組。此類干預措施對於維持市場動能和降低全球吸菸率至關重要，世界衛生組織 (WHO) 在 2025 年 10 月發布的報告顯示，到 2024 年，全球女性菸草使用率將降至 6.6%。

市場挑戰

ニコチン置換療法（NRT）市場の成長における大きな障害は、NRT製品の安全性と有効性に対する消費者の根強い懐疑心であり、これが潜在的な利用者の転換率を直接低下させています。多くの人は禁煙を望んでいるにもかかわらず、不信感からこれらの医療已通過核准補助剤の利用を躊躇しています。皮膚の炎症や吐き気などの副作用を恐れたり、NRTが単に一つの成癮を別の成癮に置き換えるだけであり、それによって政府規制のプラスの効果が相殺されると信じたりしているためです。こうした信頼の欠如は、新興経済国において特に深刻な問題となっています。これらの国々では、啓発活動が不十分であるため誤解が助長され、世界の禁煙の取り組みにもかかわらず、導入率が伸び悩んでいます。世界保健機関（WHO）の2025年の調査結果によると、世界の喫煙率は依然として約19.5％にとどまっており、これは、主にNRT製品をめぐる根強い疑念や誤った情報により、依然として禁煙療法に移行していない人口層が相当数存在することを浮き彫りにしています。

市場趨勢

重塑尼古丁替代療法（NRT，即淨戒菸療法）領域的關鍵趨勢之一是將數位療法與連網裝置結合。這些療法結合了藥物輔助和行為支持系統，旨在促進長期戒菸。各公司正在推出行動應用程式和數位診所，提供認知行為療法（CBT）、即時菸癮追蹤和遠端指導，從而提高用戶留存率，並解決僅靠實體產品無法解決的成癮心理問題。這種綜合方法顯著改善了戒菸效果。 Pelago公司2025年6月的一項研究表明，其數位化整合的戒菸計畫在28天後實現了52%的生化檢驗戒菸率。同時，市場正朝著「速效」和「靈活給藥方案」的方向發展，推動了旨在快速緩解症狀並模擬可燃香菸即時效果的先進給藥系統的研發。製造商們正從緩釋貼片轉向攜帶式霧化器和吸入器，旨在透過肺部吸收快速緩解症狀，從而縮短戒斷期並降低復發率。 Qnovia公司於2025年1月啟動的RespiRx尼古丁吸入器I期臨床試驗清晰地展現了這種對「快速起效」和「生物利用度」的關注。該試驗評估了一種新型振篩孔式噴霧器，預計其藥物動力學性能優於現有的替代療法。

目錄

第1章：引言

第2章 分析方法

第3章執行摘要

第4章：客戶心聲

第5章：全球尼古丁替代療法市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（尼古丁替代療法（吸入器、口香糖、經皮吸收貼片、舌下片、錠劑等）、電子菸、加熱菸草製品）
    • 分銷通路（線下、線上）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美尼古丁替代療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲尼古丁替代療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區尼古丁替代療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲尼古丁替代療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲尼古丁替代療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 企業合併（M&A）
  • 產品發布
  • 近期趨勢

第13章：全球尼古丁替代療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客購買力
  • 替代品的威脅

第15章 競爭格局

  • Cipla Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Philip Morris Products SA
  • British American Tobacco plc
  • Japan Tobacco, Inc.
  • Imperial Brands PLC
  • Glenmark Ltd

第16章 策略建議

第17章：關於TSCI與免責聲明

簡介目錄
Product Code: 17578

The Global Nicotine Replacement Therapy (NRT) Market is projected to expand significantly from USD 55.09 Billion in 2025 to USD 88.84 Billion by 2031, achieving an 8.29% compound annual growth rate. NRT encompasses medically approved products like patches, gums, lozenges, and inhalers, designed to deliver controlled nicotine doses to alleviate withdrawal symptoms without the harmful toxins present in combustible tobacco. This market growth is primarily driven by stringent global government regulations on tobacco use and increasing public awareness of smoking's severe health risks, factors which fundamentally sustain the demand for cessation aids. Reinforcing this trend, the World Health Organization reported a decrease in global tobacco users to approximately 1.2 billion in 2025, demonstrating the substantial impact of these public health initiatives on quitting behaviors.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 55.09 Billion
Market Size 2031USD 88.84 Billion
CAGR 2026-20318.29%
Fastest Growing SegmentE-cigarettes
Largest MarketNorth America

Market Driver

The Global Nicotine Replacement Therapy Market is principally driven by a growing consumer awareness of the severe health consequences associated with combustible tobacco, prompting smokers to seek clinically proven cessation aids. Public health campaigns effectively highlight smoking's link to life-threatening conditions, leading to behavioral changes and a rising adoption of NRT products such as gums, patches, and lozenges as harm-reduction strategies; the American Cancer Society noted a historic low of 11% in U.S. adult cigarette smoking prevalence in 2023, reflecting the profound effect of health risk understanding. Concurrently, technological advancements are enhancing NRT efficacy and user compliance through innovative delivery systems that better mimic smoking's physiological satisfaction without toxicity, thereby addressing high relapse rates. For example, Achieve Life Sciences' novel cytisinicline-based treatment demonstrated a statistically significant 30.3% continuous abstinence rate over twelve weeks in the ORCA-3 Clinical Trial in April 2025, significantly outperforming placebo. Such interventions are pivotal for market momentum and reducing global smoking rates, as evidenced by the World Health Organization's report in October 2025, showing a decline in global tobacco use among women to just 6.6% in 2024.

Market Challenge

A significant impediment to the Nicotine Replacement Therapy (NRT) market's growth is persistent consumer skepticism regarding the safety and efficacy of NRT products, which directly reduces the conversion rate of potential users. Many individuals, despite desiring to quit smoking, hesitate to adopt these medically approved aids due to mistrust, fearing adverse side effects like skin irritation or nausea, or believing NRT merely substitutes one addiction for another, thereby neutralizing the positive impact of government regulations. This lack of trust is particularly problematic in emerging economies where insufficient educational outreach exacerbates misconceptions, leading to stagnant adoption rates despite global cessation efforts. The World Health Organization's 2025 finding that global tobacco use prevalence remained at approximately 19.5 percent underscores the substantial population segment yet to transition to cessation therapies, largely due to prevailing doubts and misinformation surrounding NRT products.

Market Trends

A key trend reshaping the NRT sector is the integration of Digital Therapeutics and Connected Devices, which combine pharmacological aids with behavioral support systems to foster long-term abstinence. Companies are increasingly launching mobile applications and digital clinics that provide Cognitive Behavioral Therapy (CBT), real-time craving tracking, and remote coaching, thereby enhancing user adherence and addressing the psychological aspects of addiction that physical products alone cannot resolve. This integrated approach significantly improves cessation outcomes, as Pelago's June 2025 study demonstrated a 52% biochemically-verified quit rate after 28 days with their digitally integrated cessation program. Simultaneously, the market is observing a shift toward Fast-Acting and Flexible Dosing Solutions, driving the development of advanced delivery systems designed to rapidly alleviate symptoms and mimic the quick onset of combustible cigarettes. Manufacturers are moving beyond slow-release patches to engineer portable nebulizers and inhalers that offer immediate relief via pulmonary absorption, aiming to close the craving gap and reduce relapse. This focus on speed and bioavailability is highlighted by Qnovia's January 2025 initiation of a Phase 1 clinical trial for their RespiRx Nicotine Inhaler, evaluating a new vibrating mesh nebulizer promising superior pharmacokinetics compared to existing replacement therapies.

Key Market Players

  • Cipla Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Philip Morris Products S.A
  • British American Tobacco p.l.c.
  • Japan Tobacco, Inc.
  • Imperial Brands PLC
  • Glenmark Ltd

Report Scope

In this report, the Global Nicotine Replacement Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nicotine Replacement Therapy Market, By Product

  • Nicotine Replacement Therapy
  • E-cigarettes
  • Heat-not-burn Tobacco Products

Nicotine Replacement Therapy Market, By Distribution Channel

  • Offline
  • Online

Nicotine Replacement Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nicotine Replacement Therapy Market.

Available Customizations:

Global Nicotine Replacement Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nicotine Replacement Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Nicotine Replacement Therapy (Inhalers, Gum, Transdermal Patches, Sublingual Tablets, Lozenges, Others), E-cigarettes, Heat-not-burn Tobacco Products)
    • 5.2.2. By Distribution Channel (Offline, Online)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Nicotine Replacement Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nicotine Replacement Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Nicotine Replacement Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Nicotine Replacement Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Nicotine Replacement Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nicotine Replacement Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Nicotine Replacement Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Nicotine Replacement Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Nicotine Replacement Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Nicotine Replacement Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Nicotine Replacement Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nicotine Replacement Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Nicotine Replacement Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Nicotine Replacement Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Nicotine Replacement Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Nicotine Replacement Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Nicotine Replacement Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nicotine Replacement Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Nicotine Replacement Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Nicotine Replacement Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Nicotine Replacement Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nicotine Replacement Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Nicotine Replacement Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Nicotine Replacement Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nicotine Replacement Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cipla Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Johnson & Johnson Services, Inc.
  • 15.4. Philip Morris Products S.A
  • 15.5. British American Tobacco p.l.c.
  • 15.6. Japan Tobacco, Inc.
  • 15.7. Imperial Brands PLC
  • 15.8. Glenmark Ltd

16. Strategic Recommendations

17. About Us & Disclaimer